2,6-dichlorobenzenethiol

We are 2,6-dichlorobenzenethiol CAS:24966-39-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,6-dichlorobenzenethiol
CAS.NO:24966-39-0
Synonyms:2,6-dichlorobenzenethiol
2,6-dichlorothiphenol
2,6-dichlorthiophenol
2,6-dichlorobenzene-1-thiol
2,6-dichlorophenylthiol
2,6-Dichlorothiophenol
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 246.1±20.0 °C at 760 mmHg
Melting Point 48-50 °C(lit.)
Molecular Formula C6H4Cl2S
Molecular Weight 179.067
Flash Point 97.5±21.2 °C
 
Specification:
Appearance:Off-white powder or lumps
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Butoconazole

2,6-dichlorobenzenethiol


Related News: The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.2,8-dibromodibenzofuran The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.123-54-6 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2-Methyl-1-butanethiol CAS:1878-18-8 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
2,3,5,6-Tetrafluoro-4-methylbenzyl alcohol View Details
Cytidine-5′-diphosphate disodium salt View Details
3-Bromo-4-methylbenzonitrile View Details
3-Bromo-2-chloro-5-(trifluoromethyl)pyridine manufacturer 5-fluorocytidine manufacturer 1H-1,2,4-triazole manufacturer 2-Chloro-N-methylacetamide manufacturer Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride manufacturer